Cargando…

Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib

INTRODUCTION: In Brazil, patients with chronic myeloid leukemia (CML) in the chronic phase were not given first-line imatinib treatment until 2008. Therefore, there was a long period of time between diagnosis and the initiation of imatinib therapy for many patients. This study aims to compare the ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Scerni, Ana Carolina Costa, Alvares, Leonardo Azevedo, Beltrão, Ana Cristina, Bentes, Iê Regina, Azevedo, Tereza Cristina, Bentes, Alessandra Quinto, Lemos, José Alexandre Rodrigues
Formato: Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728184/
https://www.ncbi.nlm.nih.gov/pubmed/19690655
http://dx.doi.org/10.1590/S1807-59322009000800004
_version_ 1782170723981197312
author Scerni, Ana Carolina Costa
Alvares, Leonardo Azevedo
Beltrão, Ana Cristina
Bentes, Iê Regina
Azevedo, Tereza Cristina
Bentes, Alessandra Quinto
Lemos, José Alexandre Rodrigues
author_facet Scerni, Ana Carolina Costa
Alvares, Leonardo Azevedo
Beltrão, Ana Cristina
Bentes, Iê Regina
Azevedo, Tereza Cristina
Bentes, Alessandra Quinto
Lemos, José Alexandre Rodrigues
author_sort Scerni, Ana Carolina Costa
collection PubMed
description INTRODUCTION: In Brazil, patients with chronic myeloid leukemia (CML) in the chronic phase were not given first-line imatinib treatment until 2008. Therefore, there was a long period of time between diagnosis and the initiation of imatinib therapy for many patients. This study aims to compare the major molecular remission (MMR) rates of early versus late imatinib therapy in chronic phase CML patients. METHODS: Between May 2002 and November 2007, 44 patients with chronic phase CML were treated with second-line imatinib therapy at the Hematology Unit of the Ophir Loyola Hospital (Belém, Pará, Brazil). BCR-ABL transcript levels were measured at approximately six-month intervals using quantitative polymerase chain reaction. RESULTS: The early treatment group presented a 60% probability of achieving MMR, while the probability for those patients who received late treatment was 40%. The probability of either not achieving MMR within one year of the initiation of imatinib therapy or losing MMR was higher in patients who received late treatment (79%), compared with patients who received early treatment (21%, odds ratio=5.75, P=0.012). The probability of maintaining MMR at 30 months of treatment was 80% in the early treatment group and 44% in the late treatment group (P=0.0005). CONCLUSIONS: For CML patients in the chronic phase who were treated with second-line imatinib therapy, the probability of achieving and maintaining MMR was higher in patients who received early treatment compared with those patients for whom the time interval between diagnosis and initiation of imatinib therapy was longer than one year.
format Text
id pubmed-2728184
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-27281842009-08-18 Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib Scerni, Ana Carolina Costa Alvares, Leonardo Azevedo Beltrão, Ana Cristina Bentes, Iê Regina Azevedo, Tereza Cristina Bentes, Alessandra Quinto Lemos, José Alexandre Rodrigues Clinics (Sao Paulo) Clinical Sciences INTRODUCTION: In Brazil, patients with chronic myeloid leukemia (CML) in the chronic phase were not given first-line imatinib treatment until 2008. Therefore, there was a long period of time between diagnosis and the initiation of imatinib therapy for many patients. This study aims to compare the major molecular remission (MMR) rates of early versus late imatinib therapy in chronic phase CML patients. METHODS: Between May 2002 and November 2007, 44 patients with chronic phase CML were treated with second-line imatinib therapy at the Hematology Unit of the Ophir Loyola Hospital (Belém, Pará, Brazil). BCR-ABL transcript levels were measured at approximately six-month intervals using quantitative polymerase chain reaction. RESULTS: The early treatment group presented a 60% probability of achieving MMR, while the probability for those patients who received late treatment was 40%. The probability of either not achieving MMR within one year of the initiation of imatinib therapy or losing MMR was higher in patients who received late treatment (79%), compared with patients who received early treatment (21%, odds ratio=5.75, P=0.012). The probability of maintaining MMR at 30 months of treatment was 80% in the early treatment group and 44% in the late treatment group (P=0.0005). CONCLUSIONS: For CML patients in the chronic phase who were treated with second-line imatinib therapy, the probability of achieving and maintaining MMR was higher in patients who received early treatment compared with those patients for whom the time interval between diagnosis and initiation of imatinib therapy was longer than one year. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2009-08 /pmc/articles/PMC2728184/ /pubmed/19690655 http://dx.doi.org/10.1590/S1807-59322009000800004 Text en Copyright © 2009 Hospital das Clínicas da FMUSP
spellingShingle Clinical Sciences
Scerni, Ana Carolina Costa
Alvares, Leonardo Azevedo
Beltrão, Ana Cristina
Bentes, Iê Regina
Azevedo, Tereza Cristina
Bentes, Alessandra Quinto
Lemos, José Alexandre Rodrigues
Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
title Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
title_full Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
title_fullStr Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
title_full_unstemmed Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
title_short Influence of Late Treatment on How Chronic Myeloid Leukemia Responds to Imatinib
title_sort influence of late treatment on how chronic myeloid leukemia responds to imatinib
topic Clinical Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2728184/
https://www.ncbi.nlm.nih.gov/pubmed/19690655
http://dx.doi.org/10.1590/S1807-59322009000800004
work_keys_str_mv AT scernianacarolinacosta influenceoflatetreatmentonhowchronicmyeloidleukemiarespondstoimatinib
AT alvaresleonardoazevedo influenceoflatetreatmentonhowchronicmyeloidleukemiarespondstoimatinib
AT beltraoanacristina influenceoflatetreatmentonhowchronicmyeloidleukemiarespondstoimatinib
AT bentesieregina influenceoflatetreatmentonhowchronicmyeloidleukemiarespondstoimatinib
AT azevedoterezacristina influenceoflatetreatmentonhowchronicmyeloidleukemiarespondstoimatinib
AT bentesalessandraquinto influenceoflatetreatmentonhowchronicmyeloidleukemiarespondstoimatinib
AT lemosjosealexandrerodrigues influenceoflatetreatmentonhowchronicmyeloidleukemiarespondstoimatinib